Compugen Execs Trade Their Own Stock, Yet Confidence Grows Amid Sky‑High Gains
Insider trades by Compugen SVP and CEO reveal disciplined buying‑selling patterns that align with the company’s sharp price gains, hinting at sustained confidence in its oncology genomics platform.
3 minutes to read